Anika Therapeutics Inc.

NASDAQ: ANIK · Real-Time Price · USD
8.63
-0.45 (-4.96%)
At close: Aug 14, 2025, 3:59 PM
8.75
1.39%
After-hours: Aug 14, 2025, 05:55 PM EDT

Anika Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
119.91M 166.66M 156.24M 147.79M
Cost of Revenue
43.91M 63.57M 62.66M 64.85M
Gross Profit
76M 103.09M 93.58M 82.94M
Operating Income
-5.1M -87.64M -19.4M -18.48M
Interest Income
n/a n/a 654K 188K
Pretax Income
-2.76M -85.33M -18.75M 2.43M
Net Income
-56.38M -82.67M -14.86M 4.13M
Selling & General & Admin
55.55M 95.85M 84.79M 74.1M
Research & Development
25.54M 32.69M 28.18M 27.33M
Other Expenses
n/a 62.19M n/a n/a
Operating Expenses
81.1M 191.47M 112.98M 101.42M
Interest Expense
n/a n/a 654K n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
125.01M 254.3M 175.64M 166.27M
Income Tax Expense
6.06M -2.66M -3.89M -1.71M
Shares Outstanding (Basic)
14.72M 14.66M 14.56M 14.4M
Shares Outstanding (Diluted)
14.72M 14.66M 14.56M 14.63M
EPS (Basic)
-3.83 -5.64 -1.02 0.29
EPS (Diluted)
-3.83 -5.64 -1.02 0.28
EBITDA
3.02M -11.23M -4.91M 2.62M
EBIT
-5.1M -25.45M -19.4M -18.48M
Depreciation & Amortization
8.12M 14.22M 16.35M 15.99M